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Biobanks: the need for standardization
Biobanks are heterogeneous in their design and use, and 
they range in size from, say, 1,000 patients to 500,000 or 
more volunteers. They may contain data and samples from 
family studies, or from patients with a specific disease 
(plus ideally, matched controls), or they may be part of 
large-scale epidemiologic collections, or collections from 
clinical trials of new medical interventions. The samples 
collected  will  typically  include  whole  blood  and  its 
fractions,  extracted  genomic  DNA,  whole  cell  RNA, 
urine, as well as, variously, saliva, nail clippings, hair and 
a  variety  of  other  tissues  and  material  relevant  to  the 
design  of  specific  studies.  Inevitably,  data  and  samples 
are  collected  under  different  conditions,  to  different 
standards and for different purposes. Some biobanks take 
a highly centralized approach to the collection, proces-
sing and archiving of samples (for example, UK Biobank 
[1]) where participant samples undergo minimal proces-
sing at the collection site, but are shipped to a central 
processing  and  storage  facility.  While  ensuring  robust 
quality  control  and  data  integrity  and  security,  this 
approach inevitably introduces a delay between collec-
tion and cryopreservation that may result in the loss of 
labile  species  in  the  samples.  Conversely,  other  large 
studies  will  aim  to  collect  and  process  participant 
samples as quickly as possible (for example, the American 
Cancer  Society  Cancer  Prevention  Study-3  [2]).  Here, 
samples are collected at fundraising events and in work-
place settings and are processed within a few hours by 
local laboratories before low-temperature archiving. The 
challenges here are to maintain consistency of collection, 
shipping and processing. A hybrid approach is taken in 
other  studies  where  a  proportion  of  the  participant 
samples are processed and stored locally, with a second set 
stored in a centralized archive. Here the challenges lie in 
process consistency, inventory control, and manage  ment 
of the use of the depletable aspects of the resource. This 
method is being considered for the Helmholtz consortium 
Biobank, which is under development in Germany.
Not surprisingly, given the challenges of data collection 
and sample storage within particular studies, there has 
been little standardization across biobanks. However, a 
number of international initiatives are aiming to provide 
guidance  and  protocols  to  address  this  issue  going 
forward (for example, the DataSHaPER tools developed 
by the Public Population Project in Genomics (P3G) [3]). 
The  aim  is  to  facilitate  data  sharing  between  different 
resources,  thereby  increasing  effective  sample  size  and 
statistical power, especially for rare diseases [4]. Rather 
than  striving  for  uniformity  across  diverse  studies,  we 
believe  it  is  more  realistic  to  focus  on  developing  and 
testing  protocols  that  produce  high-quality  data  and 
samples, with full information describing their collection 
and processing. In this way, studies will be optimized for 
the  specific  questions  being  investigated,  while  also 
potentially contributing to collaborative efforts that take 
advantage of samples from several biobanks.
Design and implementation of biobanks: what are 
the basics?
Four  key  areas  should  be  addressed  in  designing  and 
implementing biobanks, regardless of their size and use.
Abstract
Biobanks are diverse in their design and purpose; the 
idea of fully harmonizing historical and future biobanks 
is unaffordable and unfeasible. Biobanks should focus 
their efforts instead on developing and maintaining 
high-quality collections of samples capable of 
providing a wide range of biological information using 
processes that minimize introduced variability. A full 
data audit trail on sample processing, archiving, and 
quality control procedures should also be provided. 
This should enable the data derived from biobanks to 
contribute as part of wider collaborative efforts with 
other similar resources.
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main recruitment starts
An important early decision is whether samples collected 
from volunteers at multiple locations should be processed 
as quickly as possible at the collection site or shipped to a 
central  processing  facility.  The  first  approach  has  the 
advantage that parameters that are rapidly lost within a 
sample  may  be  captured,  as  well  as  avoiding  possible 
degradation of the latent information during shipment; 
the second allows for a centralized approach to sample 
handling and processing, which may be cost-effective and 
result in better quality control. Either way, it is essential 
to minimize, as far as possible, the impact of the collec-
tion, processing, shipping and archiving protocol on the 
integrity of the samples. This requires properly designed 
pilot studies followed by robust procedures to ensure that 
the samples are collected, processed and handled strictly 
according to protocol [5-7].
Future proof the sample collection
While some studies involving biobanks are designed to 
address specific questions, they may find broader use in 
the future (particularly as new or lower-cost analytical 
technologies  become  available).  Collecting  and  proces-
sing samples from large numbers of volunteers is expen-
sive and time consuming. During the design stage, it is 
therefore  important  to  consider  whether  collection  of 
additional  samples  will  have  the  potential  to  produce 
useful data in the future, either as an adjunct to the study 
in hand or as part of a broader biobanking initiative. If 
possible, samples should be collected in a way that will 
allow as wide a range of assay types as can be predicted. 
As an example, UK Biobank collects a range of biological 
samples  (blood,  urine,  saliva)  that  were  tested  in  pilot 
studies  using  different  analytical  techniques,  including 
standard  biochemistry,  proteomics  and  metabonomics 
[5,6].  In  order  to  future  proof  the  samples  as  far  as 
possible,  both  plasma  and  serum  were  collected  in  a 
range  of  tubes  with  different  additives  (Figure  1).  A 
similar set of samples is being collected in the Ontario 
Health Study [8].
Implement quality programs from the start of the study
The sample collection and processing protocol should be 
underpinned by a study-wide quality program with the 
aim  of  producing  samples  and  data  that  are  fit  for 
research purposes. This should include quality assurance 
(preventing  errors  and  variability  from  occurring)  and 
quality  control  procedures  (detecting  errors  and  varia-
bility if they occur) that should be built into the study 
design from the outset. Many studies are implementing 
quality schemes, such as ISO9001:2008; these are suited 
to biobanks because they focus specifically on the quality 
of the samples and data. ISO accreditation also requires 
measurement  of  critical  processes  (for  example,  time 
from sample collection to ultra-low-temperature archiv-
ing) and continuous improvement efforts to optimize the 
performance of the organization. In UK Biobank, there 
has been the successful transfer of much from Japanese 
manufacturing quality approaches to optimize tech  nol-
ogy, processes and systems involved in sample processing 
[7]. By paying careful attention to the critical points in 
the pathway, it has been possible to reduce the time from 
sample  collection  to  ultra-low-temperature  archiving 
from  an  average  25.6  h  (standard  deviation  =  3.5)  to 
24.6 h (standard deviation = 2.6), close to the target of 
24 h based on pilot studies [9].
Centralize and standardize as much as possible and limit 
the impact of variability
As  noted,  the  degree  to  which  sample  collection  and 
processing can be centralized will vary between studies. 
However, standardization and centralization of proces-
sing at a dedicated single site bring benefits in robustness 
of the data trail, reduced cost and increased achievable 
throughput and accuracy of sample handling and picking; 
for example, through the use of automation (Figure 2). It 
also limits the impact of analytical variability and thereby 
improves the power of subsequent analyses in which data 
derived  from  the  samples  are  used.  What  should  be 
avoided  at  all  costs  is  non-detectable  systematic  error 
introduced by variable (typically manual) processing at 
multiple sites. Given that these resources are established 
to  explore  the  etiology  of  complex  diseases  where  the 
impact of exposure to specific risk factors will often be 
low (odds ratio typically 1.5 or below), this type of error 
Figure 1. Sample collection, processing and archiving in the 
UK Biobank baseline assessment visit. A variety of samples 
are collected in different collection vessels appropriate to their 
anticipated end use. Samples are fractionated and stored as aliquots 
in one of two low-temperature archives to protect them from 
degradation caused by freeze-thawing, or loss due to breakdown of 
a single archive site. Footnote to Figure 1: DMSO, dimethyl sulfoxide; 
EDTA, ethylenediaminetetraacetic acid; PST, plasma separator tube; 
SST, serum separator tube.
Vacutainer
tube
Fraction
Number of aliquots
-80oC Liquid N2
EDTA (9ml) x 2
Plasma 6 2
Buffy coat 1 1
Red cells 0 2
Lithium heparin (PST) Plasma 3 1
Silica clot activator (SST) Serum 3 1
Acid citrate dextrose DMSO blood - 2
Tempus tube Whole blood (RNA) - 6
Saliva Mixed saliva sample - 2
EDTA (4 ml)
Hematology
(Immediate)
- -
Urine Urine 4 2
Total aliquots 17 19
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causative associations. This effect may be exacerbated in 
prospective  cohorts  where  case-control  studies  are 
nested within the sample, especially if cases and controls 
are drawn differentially from different sites. If processing 
occurs at local sites, substantial effort should be directed 
into  training  of  staff  to  agreed  and  validated  operating 
procedures and in monitoring their performance to ensure 
quality  standards  are  maintained.  Cross-validation 
between sites will also be required. The problem of locally 
introduced  variability  through  processing  may  be 
exacerbated if disease-specific studies use case and control 
samples from different collections. It is only by ensuring 
rigorous consistency and quality within individual studies 
that  biobanks  can  collaborate  effect  ively  and  start  to 
exploit the potential of the very large ‘virtual’ sample size 
being created across biobanks internationally.
Conclusions
Rather  than  attempting  to  standardize  biobanks  to  a 
uniform  design,  effort  should  be  focused  on  designing 
and testing the sample collection protocol in a way that 
produces high-quality data and samples for research use. 
A full data audit trail should be generated on the sample 
collection process to allow collaborative use of samples 
and data across different biobanks. It is vital that quality 
programs  are  implemented  to  minimize  the  effect  of 
introduced variability on the integrity of the samples and, 
where possible, consideration should be given to future 
proofing  the  collection.  In  this  way  sample  biobanks 
should continue to provide valuable information well into 
the future and provide a long-term return on the initial 
investment in establishing the resource.
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Figure 2. Sample storage and aisle robotics used to archive and 
retrieve samples in UK Biobank. Samples identified by individual 
barcodes are held in automation compatible racks at -80°C in 
independent storage towers maintained at temperature by liquid 
nitrogen circulating in a closed evaporator system. All sample transfer 
and retrieval processes are automated to ensure accuracy and speed.
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